Many Americans Have COVID-19 Vaccine Preferences
THURSDAY, April 29, 2021 -- Nearly three-quarters of Americans say they have a preference for a specific COVID-19 vaccine, a new survey finds.
The poll of 1,000 people found that most (36 percent) preferred Pfizer, followed by Moderna at 19 percent and Johnson & Johnson at 17 percent, CBS News reported.
Reasons cited for wanting the Pfizer vaccine include the vaccine's efficacy (45 percent), positive study data (35 percent), reportedly fewer side effects (32 percent), reading a positive news story (29 percent), and social media posts by family and friends (21 percent), according to the results of the survey by M Booth Health, a health communications consultancy, and Savanta, a market research and advisory company.
Among those who preferred the Moderna vaccine, common reasons included efficacy (32 percent), fewer side effects (31 percent), positive study data (30 percent), and social media posts by family and friends (23 percent), CBS News reported.
Those who wanted the Johnson & Johnson vaccine listed reasons such as the fact that it requires only one shot (31 percent), preexisting trust in the brand (26 percent), or "good experiences" with the company's products in the past (19 percent).
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Further Support and Information on COVID-19
Read this next
FRIDAY, May 14, 2021 -- Patients hospitalized with COVID-19 may be at risk for developing new heart failure, according to a research letter published in the May 4 issue of the...
FRIDAY, May 14, 2021 -- Many U.S. adults remain unprotected against vaccine-preventable diseases, according to research published in the May 14 issue of the U.S. Centers for...
THURSDAY, May 13, 2021 -- The U.S. Centers for Disease Control and Prevention said Wednesday that COVID-19 vaccines can be given along with other childhood shots, CNN reported...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.